

Resumption of the downgraded circuit during a chemotherapy

prescription software breakdown from A to Z.

CHABANOL C., DUCASSOU M-L., BAY M., DELRIEU J. Pharmacie à Usage Intérieur, CHU de Poitiers



COM23-73566

CONTEXT:

Computerization has made product flow easier, but what impact would a failure of the prescription software (CHIMIO®) have ? In order to limit this impact, the entire circuit has been reviewed, from prescription to release.

MATERIEL ET METHOD :

- Bi-annual recording of active chemotherapy protocols then made available on the Intranet,
- Request for a daily recording of the prescriptions and manufacturing sheets of the CHIMIO[®] software,
- Use of Excel: creation of a prescription aid framework and manufacturing sheet,
- Comparative situation CHIMIO® vs Excel: prescriptions and manufacturing sheets of CHIMIO® taken over Excel in order to highlight the discrepancies (of dosage, expiry dates, rounding, volume, expiry date, etc.).

CONCLUSION :

The simulation made it possible to qualify the formulas used and to add more (formula for calculating the pediatric body surface area), to verify the reliability of the data used and to highlight a 100% increase in the duration of medical prescription and pharmaceutical validation. The modifications have allowed to make the circuit safe while getting closer to CHIMIO® data. The recordings put in place allow access to the protocols (molecule, dosage, solvent, duration and order of administration), but also to have an eye on the patient's last treatment.

In the meantime, the procedure was put into a real situation during a software failure (duration of approximately 6 hours), allowing the launch of around 15 chemotherapy for naive patients.



recommendations (for example for an aberrant dosage of 2200mg of Melphalan):



Result of comparative situation of 54 molecules :

- 5 molecules: with a difference in volume (without impact on the dosage) because no data on the maximum volume of the pockets at the time of the simulation.
- **1** molecule for pediatric use with a 3% increase in dosage (different body surface area calculation formula for the pediatric population).
- 4 molecules with a dose difference of less than 4% (bad concentration in the vial taken into account).